Ptc Therapeutics Stock Price To Earnings To Growth
| PTCT Stock | USD 55.31 0.96 1.71% |
PTC Therapeutics fundamentals help investors to digest information that contributes to PTC Therapeutics' financial success or failures. It also enables traders to predict the movement of PTC Stock. The fundamental analysis module provides a way to measure PTC Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PTC Therapeutics stock.
PTC | Price To Earnings To Growth |
PTC Therapeutics Company Price To Earnings To Growth Analysis
PTC Therapeutics' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current PTC Therapeutics Price To Earnings To Growth | 0.81 X |
Most of PTC Therapeutics' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PTC Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PTC Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for PTC Therapeutics is extremely important. It helps to project a fair market value of PTC Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since PTC Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PTC Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PTC Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
PTC Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, PTC Therapeutics has a Price To Earnings To Growth of 0.81 times. This is 14.08% higher than that of the Biotechnology sector and 74.2% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 83.44% higher than that of the company.
PTC Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PTC Therapeutics' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PTC Therapeutics could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics of similar companies.PTC Therapeutics is currently under evaluation in price to earnings to growth category among its peers.
PTC Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of PTC Therapeutics from analyzing PTC Therapeutics' financial statements. These drivers represent accounts that assess PTC Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PTC Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 4.0B | 2.8B | 2.7B | 2.1B | 3.5B | 3.6B | |
| Enterprise Value | 4.2B | 2.5B | 3.0B | 3.7B | 3.1B | 3.2B |
PTC Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, PTC Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to PTC Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
PTC Fundamentals
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0509 | ||||
| Profit Margin | (0.45) % | ||||
| Operating Margin | (0.07) % | ||||
| Current Valuation | 5.77 B | ||||
| Shares Outstanding | 78.87 M | ||||
| Shares Owned By Insiders | 2.45 % | ||||
| Shares Owned By Institutions | 99.99 % | ||||
| Number Of Shares Shorted | 3.7 M | ||||
| Price To Earning | (5.67) X | ||||
| Price To Book | 1,743 X | ||||
| Price To Sales | 5.50 X | ||||
| Revenue | 806.78 M | ||||
| Gross Profit | 214.9 M | ||||
| EBITDA | (120.46 M) | ||||
| Net Income | (363.3 M) | ||||
| Cash And Equivalents | 288.43 M | ||||
| Cash Per Share | 4.01 X | ||||
| Total Debt | 389.3 M | ||||
| Current Ratio | 1.23 X | ||||
| Book Value Per Share | (14.13) X | ||||
| Cash Flow From Operations | (107.69 M) | ||||
| Short Ratio | 5.08 X | ||||
| Earnings Per Share | (4.65) X | ||||
| Price To Earnings To Growth | 0.81 X | ||||
| Target Price | 64.93 | ||||
| Number Of Employees | 939 | ||||
| Beta | 0.66 | ||||
| Market Capitalization | 4.44 B | ||||
| Total Asset | 1.71 B | ||||
| Retained Earnings | (3.65 B) | ||||
| Working Capital | 784.55 M | ||||
| Current Asset | 355.95 M | ||||
| Current Liabilities | 45.39 M | ||||
| Net Asset | 1.71 B |
About PTC Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PTC Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PTC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PTC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.